/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Jungsil Ro

Western University(CA)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

248

Papers

20.3K

Citations

59

h-index

151

i10-index

Jungsil Ro is an academic researcher from Western University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 59, co-authored 211 publications.

ORCID: 0000-0003-4411-0386

Research Topics

Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Advanced Breast Cancer Therapies Breast Lesions and Carcinomas

Papers by this author

works

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

2015 · New England Journal of Medicine · 2,084 citations

https://doi.org/10.1056/nejmoa1413513

Sandra M. Swain José Baselga Sung‐Bae Kim Jungsil Ro

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 · The Lancet Oncology · 1,795 citations

https://doi.org/10.1016/s1470-2045(15)00613-0

Massimo Cristofanilli Nicholas C. Turner Igor Bondarenko Jungsil Ro

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

2015 · New England Journal of Medicine · 1,569 citations

https://doi.org/10.1056/nejmoa1505270

Nicholas C. Turner Jungsil Ro Fabrice André Sherene Loi

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 · New England Journal of Medicine · 1,220 citations

https://doi.org/10.1056/nejmoa1810527

Nicholas C. Turner Dennis J. Slamon Jungsil Ro Igor Bondarenko

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

2013 · The Lancet Oncology · 992 citations

https://doi.org/10.1016/s1470-2045(13)70130-x

Sandra M. Swain Sung‐Bae Kim Javier Cortés Jungsil Ro

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

2020 · The Lancet Oncology · 865 citations

https://doi.org/10.1016/s1470-2045(19)30863-0

Sandra M. Swain David Miles Sung‐Bae Kim Young‐Hyuck Im

Research topics

topics

Cancer Treatment and Pharmacology

HER2/EGFR in Cancer Research

Breast Cancer Treatment Studies

Advanced Breast Cancer Therapies

Breast Lesions and Carcinomas

Chat about Author

Papers

Chat

Click to start Chat